Rheumatism (RA) is easily the most common inflammatory form of arthritis, affecting greater than 2 million Americans. It's a chronic autoimmune inflammatory ailment that causes systemic problems, meaning it can affect body organs, including the lungs, heart, bone marrow, and eye. It's also a major risk factor to build up cardiovascular complications such as stroke and cardiac arrest.

Included with these concerns may be the significant problem with rheumatoid arthritis symptoms that is that if unattended aggressively, it can cause irreversible joint damage, chronic pain, and functional disability.

arthritis foundation

Nevertheless there is still no remedy for the illness yet, RA may be treatable and also put into remission if diagnosed early and given urgency.

While many from the new medicines which have been created in recent years are effective, there's still no consensus where someone to use first, which one to make use of second, when you switch drugs, when is the best time for you to discontinue one drug and move onto another, etc.

Perhaps, in time we will be able to individualize treatment programs. Progress in the field of exactly what are called "biomarkers"- tissue evidence that may give to us a distinctive profile associated with a given patient- will require us to another level of treatment.

A bright spot is the continued development of newer therapies with assorted modes of action that will permit more choices, fewer unwanted effects, and much more convenience.

Nonetheless, what is clear today is always that delaying proper treatment contributes to functional decline which is difficult, if not impossible, to reverse.

This lack of physical function contributes to reduced productivity and increased healthcare costs.

arthritis foundation

A number of numerous studies have viewed various treatments and shown that a mixture of methotrexate, the disease-modifying anti-rheumatic drug (DMARD) of preference along with a biologic drug results in a significantly greater chance of improvement and much less odds of unemployability.

Another study has demonstrated that amount of time of disease and degree of functional impairment correlate with higher medical costs and greater disability.

Plus an additional study by Maetzel and colleagues indicated that RA costs also appear to be more than that due to other common health conditions for example osteoarthritis and hypertension (Maetzel A, et al. Ann Rheum Dis 2004; 63: 395-401).

The main hurdle today gets patients with early RA with a rheumatologist early and having the rheumatologist initiate aggressive treatment as quickly as possible. Much more about this later on articles.